Announcing this on Wednesday, India’s Pharma Secretary PD Vaghela said the new policy will also insist on globally benchmarking the Research & Development ecosystem by getting rid of archaic laws and rewarding the scientists through industry-academia linkage.
Leading vaccine major Serum Institute of India has said that it is hoping to develop a COVID-19 vaccine by the year-end, according to a report by PTI."At present, we are working on the AstraZeneca Oxford vaccine which is undergoing phase III clinical trials. In addition to this, we will also start human trials in India in August 2020. Based on the current situation and most recent updates on the clinical trials, we are hoping that the AstraZeneca Oxford vaccine will be available towards the end of this year," Serum Institute of India CEO Adar Poonawalla told PTI.
Besides scaling up production of medicines that show potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up manufacturing of drugs for chronic ailments such as asthma, COPD, among others.
Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing. Its Covihalt dosage strength has been developed keeping in mind convenience of administration.
"The company reports that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, which began on July 15, 2020, has been well tolerated," Cadila Healthcare, the listed entity of the group, said in a regulatory filing. Zydus Cadila Chairman Pankaj R Patel said the phase I dosing to establish the safety of ZyCoV-D is an important milestone.
The pandemic-induced lockdown in Sikkim has forced several drug units to halt their operations because they are in containment zones, while others have been facing challenges in accommodating their employees inside the factories.
India is staring at the risk of losing its competitive advantage in vaccine manufacturing to other countries, Biological E chairperson said, even as she also complained about lack of enough clinical trial sites and infrastructure in the country.
Earlier, Deputy Prime Minister Tatyana Golikova announced that mass production of the vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry is expected to start in September 2020.
Drug firm Cipla has witnessed three senior-level exits, including that of the company's Executive Vice-President and CEO for India business Nikhil Chopra. The other two executives are Nikhil Lalwani, head of India prescription business, and Kunal Khanna, cluster head of chronic and emerging business development and portfolio.
Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees per 200 mg tablet, making it the cheapest version available.
Jubilant Generics will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network, the company said in a release. Jubilant had entered into a non-exclusive licensing agreement with US Gilead Sciences, Inc. In May, which that granted it the right to register, manufacture and sell Gilead’s investigational drug Remdesivir in 127 countries including India.
This deal by Wockhardt entails only manufacturing the vaccine only for the United Kingdom. The government has reserved one fill and finish production line for its exclusive use for the next 18 months in order to guarantee the supply of vaccines required to fight COVID-19 in the UK, Wockhardt said in a statement.
A world without global intellectual property would be one of constant electronic warfare. State-backed hacking, such as China apparently tried with Moderna this week, would be a constant threat. Nor would companies enjoy a comfortable relationship with their own governments, who would see them less as engines of growth and more as storehouses of national wealth.